این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
سه شنبه 25 آذر 1404
Iranian Biomedical Journal
، جلد ۲۴، شماره ۶، صفحات ۳۷۰-۳۷۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells
چکیده انگلیسی مقاله
Background:
Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancy worldwide. Although the majority of EOC patients achieve clinical remission after induction therapy, over 80% relapse and succumb to the chemoresistant disease. Previous investigations have demonstrated the association of epidermal growth factor receptor (
EGFR
) with resistance to cytotoxic chemotherapies, hormone therapy, and radiotherapy in the cancers. These studies have highlighted the role of
EGFR
as an attractive therapeutic target in cisplatin-resistant EOC cells.
Methods:
The human ovarian cell lines (SKOV3 and OVCAR3) were cultured according to ATCC recommendations. The MTT assay was used to determine the chemosensitivity of the cell lines in exposure to cisplatin and erlotinib. The qRT-PCR was applied to analyze the mRNA expression of the desired genes.
Results:
Erlotinib in combination with cisplatin reduced the cell proliferation in the chemoresistant EOC cells in comparison to monotherapy of the drugs (
p
< 0.05). Moreover, erlotinib/cisplatin combination synergistically decreased the expression of anti-apoptotic and also increased pro-apoptotic genes expression (
p
< 0.05). Cisplatin alone could increase the expression of multi-drug resistant genes. The data suggested that EGFR and cisplatin drive chemoresistance in the EOC cells through MEKK signal transduction as well as through EGFR/MEKK pathways in the cells, respectively.
Conclusion:
Our findings propose that
EGFR
is an attractive therapeutic target in chemoresistant EOC to be exploited in translational oncology, and erlotinib/cisplatin combination treatment is a potential anti-cancer approach to overcome chemoresistance and inhibit the proliferation of the EOC cells.
کلیدواژههای انگلیسی مقاله
Cisplatin, Epidermal growth factor receptor, Ovarian cancer
نویسندگان مقاله
| Arash Poursheikhani
Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| Hassan Yousefi
Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| Javad Tavakoli-bazzaz
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| Seyed H. Ghaffari
Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
نشانی اینترنتی
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-822&slc_lang=other&sid=1
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
other
موضوعات مقاله منتشر شده
Cancer Biology
نوع مقاله منتشر شده
مقاله کامل
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات